Microfabrication technology for pancreatic cell encapsulation
The inadequacy of conventional insulin therapy for the treatment of Type I diabetes has stimulated research on several therapeutic alternatives, including insulin pumps and controlled-release systems for insulin. One of the most physiological alternatives to insulin injections is the transplantation...
Saved in:
Published in | Expert opinion on biological therapy Vol. 2; no. 6; p. 633 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
England
01.08.2002
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | The inadequacy of conventional insulin therapy for the treatment of Type I diabetes has stimulated research on several therapeutic alternatives, including insulin pumps and controlled-release systems for insulin. One of the most physiological alternatives to insulin injections is the transplantation of insulin-secreting cells. It is the beta-cells of the islets that secrete insulin in response to increasing blood glucose concentrations. Ideally, transplantation of such cells (allografts or xenografts) could restore normoglycaemia. However, as with most tissue or cellular transplants, the cellular grafts, particularly xenografts, are subject to immunorejection in the absence of chronic immunosuppression. Thus, it is of great interest to develop new technologies that may be used for insulin delivery or pancreatic cell transplantation. This review describes a new approach to cellular delivery based on micro- and nanotechnology. Utilising this approach, nanoporous biocapsules are bulk and surface micromachined to present uniform and well-controlled pore sizes as small as 7 nm, tailored surface chemistries and precise microarchitectures, in order to provide immunoisolating microenvironments for cells. Such a design may overcome some of the limitations associated with conventional encapsulation and delivery technologies, including chemical instabilities, material degradation or fracture and broad membrane pore sizes. |
---|---|
AbstractList | The inadequacy of conventional insulin therapy for the treatment of Type I diabetes has stimulated research on several therapeutic alternatives, including insulin pumps and controlled-release systems for insulin. One of the most physiological alternatives to insulin injections is the transplantation of insulin-secreting cells. It is the beta-cells of the islets that secrete insulin in response to increasing blood glucose concentrations. Ideally, transplantation of such cells (allografts or xenografts) could restore normoglycaemia. However, as with most tissue or cellular transplants, the cellular grafts, particularly xenografts, are subject to immunorejection in the absence of chronic immunosuppression. Thus, it is of great interest to develop new technologies that may be used for insulin delivery or pancreatic cell transplantation. This review describes a new approach to cellular delivery based on micro- and nanotechnology. Utilising this approach, nanoporous biocapsules are bulk and surface micromachined to present uniform and well-controlled pore sizes as small as 7 nm, tailored surface chemistries and precise microarchitectures, in order to provide immunoisolating microenvironments for cells. Such a design may overcome some of the limitations associated with conventional encapsulation and delivery technologies, including chemical instabilities, material degradation or fracture and broad membrane pore sizes. |
Author | Desai, Tejal A |
Author_xml | – sequence: 1 givenname: Tejal A surname: Desai fullname: Desai, Tejal A email: Tdesai@uic.edu organization: Department of Biomedical Engineering, Boston University, MA 02215, USA. Tdesai@uic.edu |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/12171507$$D View this record in MEDLINE/PubMed |
BookMark | eNo1jztPwzAUhT0U0QfsTCh_IMHXSfwYGFAFBamIBebq-tqGoNSOnHTov4fymI70nU9HOks2iyl6xq6AV9CCuoFGgWiNrkQlK1nXM7Y4ofLE5mw5jp-cC25acc7mIEBBy9WC3T53lFNAmzvCqUuxmDx9xNSn92MRUi4GjJT9d0UF-b4vfCQcxkP_I1-ws4D96C__csXeHu5f14_l9mXztL7bllQbPZUOlDTYIDlAraWxzkuQTjYaiZPCVujaKBGM9eg0BcuVlE0IwZI1QUixYte_u8PB7r3bDbnbYz7u_n-IL8RTS38 |
CitedBy_id | crossref_primary_10_1021_jp045478u crossref_primary_10_1089_dia_2005_7_684 crossref_primary_10_1039_b806446f crossref_primary_10_1016_j_biomaterials_2006_07_010 crossref_primary_10_1163_092050609X12567186470615 crossref_primary_10_1039_c2cc17690d crossref_primary_10_1002_cmr_b_10073 crossref_primary_10_1007_s11029_011_9184_z crossref_primary_10_1016_j_jconrel_2004_09_024 crossref_primary_10_1039_c2jm30888f crossref_primary_10_1002_adbi_201900086 crossref_primary_10_1039_c0lc00499e crossref_primary_10_1039_c2jm16819g crossref_primary_10_1039_c3ib20226g crossref_primary_10_1002_mabi_201200012 crossref_primary_10_1007_s10544_006_0032_1 crossref_primary_10_1016_j_tibtech_2007_09_006 crossref_primary_10_1093_icb_icr010 crossref_primary_10_1016_j_medcli_2010_12_005 crossref_primary_10_1016_j_tibtech_2004_05_005 crossref_primary_10_1071_CH06197 crossref_primary_10_1007_s13410_017_0558_1 crossref_primary_10_1002_adma_200602574 crossref_primary_10_1038_nm0103_104 crossref_primary_10_1517_17425247_2015_961420 crossref_primary_10_1007_s10439_005_9008_1 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1517/14712598.2.6.633 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 12171507 |
Genre | Research Support, U.S. Gov't, Non-P.H.S Review Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- 00X 03L 0BK 0R~ 0VX 29G 4.4 53G 5GY AAMIU AAOUU AAPWH ABBAB ABEIZ ABJNI ABJYH ABLIJ ABLKL ABVAX ABXYU ACGFS ACIEZ ADCVX ADRBQ ADTOD AECIN AENEX AEOZL AGDLA AGMLL AIJEM AIRBT AIYSM AIZAD AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU BABNJ BLEHA CAZVN CCCUG CGR CS3 CUY CVF DASJU DAWQK DKSSO DU5 EBS ECM EIF EJD F5P H13 HZ~ KRBQP KSSTO KWAYT KYCEM LJTGL M44 M4Z NPM O9- P2P RNANH TBQAZ TDBHL TERGH TFDNU TFL TFW TUROJ TZHSB V1S ~1N |
ID | FETCH-LOGICAL-c398t-d1769a4acd1a8869bde616d648ac0c7a5283972f9bead8cfb07664fffbcb9f262 |
ISSN | 1471-2598 |
IngestDate | Tue Oct 15 23:23:04 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c398t-d1769a4acd1a8869bde616d648ac0c7a5283972f9bead8cfb07664fffbcb9f262 |
PMID | 12171507 |
ParticipantIDs | pubmed_primary_12171507 |
PublicationCentury | 2000 |
PublicationDate | 2002-Aug |
PublicationDateYYYYMMDD | 2002-08-01 |
PublicationDate_xml | – month: 08 year: 2002 text: 2002-Aug |
PublicationDecade | 2000 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Expert opinion on biological therapy |
PublicationTitleAlternate | Expert Opin Biol Ther |
PublicationYear | 2002 |
SSID | ssj0020952 |
Score | 1.7887833 |
SecondaryResourceType | review_article |
Snippet | The inadequacy of conventional insulin therapy for the treatment of Type I diabetes has stimulated research on several therapeutic alternatives, including... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 633 |
SubjectTerms | Animals Biocompatible Materials Cell Transplantation - methods Diabetes Mellitus, Type 1 - therapy Diffusion Drug Delivery Systems Humans Insulin - administration & dosage Insulin Infusion Systems Insulinoma - metabolism Islets of Langerhans - cytology Microscopy, Electron, Scanning Pancreas - cytology Time Factors |
Title | Microfabrication technology for pancreatic cell encapsulation |
URI | https://www.ncbi.nlm.nih.gov/pubmed/12171507 |
Volume | 2 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ07T8MwEMctHgsL4v1GHlCXNCFJUzsZEQJVSEUdUqlbZTv2UEGpSpby6TnbebQpiMcSRXFkufdrnLuL72-EbiQ4HWG3w11fxtyNdBFXzJVwaRBSweEdz02Fd_-Z9IbR06g7qncUNNUlOffEx5d1Jf-hCteAq66S_QPZqlO4AOfAF45AGI6_YtzXq-kU4_Mi8ebkVaLcLB-EJ906hcLRCXoHxs4gKn6paUyqlXhynju6eMo4kFPHijMZgvmq8ABEqnYL61RONN-VvEFYrVorpzp4LbkQ_MTLc2G4hHx5XiNWrWJtvu0GtmIf0EJPXugRr3ErWGz2auwfQPSj3c-fWxsK2GXTJtqEWEBvbqozMkVQDS6i-aJd_priUzQM7LY5LC0QW3TVCCKMM5Huod0iCsB3Fuk-2pDTA9QaWBnxRRundVXcexu38KAWGF8cojXuuOaOgTuuuWPNHa9wP0LDx4f0vucW22C4opPEuZsFlCQsYiILWByThGeSBCQjUcyELyjT8jwJDVXCYVaIheI-JSRSSnHBExWS8BhtTd-m8hRhFSiq9YKSTLAoSCSLqE8y5lMBVumQ7AydWLOMZ1brZFwa7Pzblgu0U_-9LtG2godLXoGnlvNrg-oTXEY8SA |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Microfabrication+technology+for+pancreatic+cell+encapsulation&rft.jtitle=Expert+opinion+on+biological+therapy&rft.au=Desai%2C+Tejal+A&rft.date=2002-08-01&rft.issn=1471-2598&rft.volume=2&rft.issue=6&rft.spage=633&rft_id=info:doi/10.1517%2F14712598.2.6.633&rft_id=info%3Apmid%2F12171507&rft_id=info%3Apmid%2F12171507&rft.externalDocID=12171507 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2598&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2598&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2598&client=summon |